drug-discovery

You can assess drug-likeness and ADMET properties by searching ChEMBL for active compounds, then calculating Ro5/Veber physicochemical profiles and querying OpenFDA for safety data. This workflow integrates bioactivity search, property calculation, and safety profiling into a single pipeline.

Yes, you can retrieve bioactivity data by querying public APIs including ChEMBL, PubChem, and OpenTargets. The workflow coordinates target-based searches across these databases to identify active compounds and evaluate their pharmacological profiles.

Automating drug-interaction checks involves querying OpenFDA and OpenTargets APIs within a programmable cheminformatics workflow. This approach consolidates safety lookups and ADMET profiling, reducing manual overhead and enabling reproducible analyses.

Access to public APIs like ChEMBL, PubChem, OpenFDA, and OpenTargets is required to perform compound searches and safety profiling. The workflow uses local scripts to execute deterministic tasks, relying on these open data sources for bioactivity and drug-interaction information.

Interpreting structure-activity relationships during lead optimization involves analyzing bioactivity search results alongside drug-likeness assessments and ADMET profiles. The workflow provides guidance on evaluating these relationships to inform compound prioritization and safety.

Limitations include dependency on public API availability and data completeness from sources like ChEMBL and PubChem. The workflow performs deterministic tasks using local scripts, but relies on external databases for bioactivity, property calculation, and safety profiling data.